CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial
Sallman, Kerre, Havelange, Poiré, Lewalle, Wang, Brayer, Davila, Moors, Machiels, Awada, Alcantar-Orozco, Borissova, Braun, Dheur, Gilham, Lonez, Lehmann, Flament (2023) CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial Lancet Haematol (IF: 15.4) 10(3) e191-e202Links
http://www.ncbi.nlm.nih.gov/pubmed/36764323http://dx.doi.org/10.1016/S2352-3026(22)00378-7
